U.S. Markets close in 5 hrs 12 mins

DermTech, Inc. (DMTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.83-0.85 (-1.86%)
As of 10:48AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.68
Bid45.21 x 1100
Ask45.45 x 1400
Day's Range44.13 - 46.20
52 Week Range9.64 - 84.49
Avg. Volume1,608,953
Market Cap1.289B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateMar 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est64.25
  • 5 Top Stocks for April
    Motley Fool

    5 Top Stocks for April

    To help you invest better, we ask five Motley Fool contributors for their best ideas each month. For April, they came back with Netflix (NASDAQ: NFLX), Zillow Group (NASDAQ: Z)(NASDAQ: ZG), Axon Enterprise (NASDAQ: AXON), DermTech (NASDAQ: DMTK), and Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A).

  • 3 Beaten-Down Stocks That Could Double Your Money
    Motley Fool

    3 Beaten-Down Stocks That Could Double Your Money

    Last year, the growth stocks in the Nasdaq-100 index trounced the staid giants in the Dow Jones Industrial Average. DermTech (NASDAQ: DMTK) markets an exciting product: a skin genomics test that can detect melanoma more accurately and cheaper than surgical biopsy. Part of the problem was the aforementioned general sell-off of growth stocks.

  • Motley Fool

    Should Investors Be Worried About DermTech's Decline From Its 52-Week Highs?

    DermTech (NASDAQ: DMTK) is trading well off its 52-week high of $84.49 per share while investors try to figure out how to value the prospects of the dermatology company. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights talk about what the company is doing to grow sales of its melanoma test and why the recent decline shouldn't be a big concern for long-term investors. Brian Orelli: Max asks, any info or thoughts on DermTech following and its prospects, bought it a high valuation and think they are creating fantastic products, so the sell-off is a little disconcerting.